Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Vaccitech Plc ADR (NQ: VACC ) N/A UNCHANGED Last Price Updated: 4:00 PM EST, Nov 6, 2023 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 0 Open - Bid (Size) 4.950 (1) Ask (Size) 5.180 (5) Prev. Close 5.000 Today's Range N/A - N/A 52wk Range 1.640 - 4.540 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Vaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity, and Cancer November 06, 2023 From Barinthus Biotherapeutics Via GlobeNewswire 12 Health Care Stocks Moving In Tuesday's After-Market Session October 31, 2023 Via Benzinga Performance More News Read More Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday October 09, 2023 Via InvestorPlace Analyst Expectations for Vaccitech's Future June 13, 2023 Via Benzinga Vaccitech: Q1 Earnings Insights May 12, 2023 Via Benzinga Vaccitech Earnings Perspective: Return On Capital Employed March 27, 2023 Via Benzinga 12 Health Care Stocks Moving In Tuesday's Intraday Session September 26, 2023 Via Benzinga 12 Health Care Stocks Moving In Tuesday's Pre-Market Session September 26, 2023 Via Benzinga 12 Health Care Stocks Moving In Monday's Intraday Session September 25, 2023 Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For September 25, 2023 September 25, 2023 Via Benzinga Investigational Immunotherapy Treatments Offering Promise in Treating Pancreatic Cancer as Risk Factors Rise September 26, 2023 Via FinancialNewsMedia Vaccitech to Host KOL Webinar on Seeking a Functional Cure for Chronic Hepatitis B on September 20, 2023 September 13, 2023 From Vaccitech plc Via GlobeNewswire Stocks That Hit 52-Week Lows On Monday September 11, 2023 Via Benzinga Vaccitech Reports Second Quarter 2023 Financial Results and Recent Corporate Developments August 10, 2023 From Vaccitech plc Via GlobeNewswire Stocks That Hit 52-Week Lows On Thursday September 07, 2023 Via Benzinga 12 Health Care Stocks Moving In Tuesday's After-Market Session July 04, 2023 Via Benzinga Vaccitech to Present Positive Final Data at EASL Congress for Phase 1b/2 HBV002 Study in Adults with Chronic Hepatitis B June 21, 2023 From Vaccitech plc Via GlobeNewswire Arbutus Doses First Patient in Additional Treatment Arm of Phase 2a Triple Combination Clinical Trial that Includes a PD-1 Monoclonal Antibody June 21, 2023 From Arbutus Biopharma Corporation Via GlobeNewswire Vaccitech Doses First Patient in PCA001, a Prostate Cancer Phase 1/2 Clinical Trial of VTP-850 Immunotherapeutic Candidate in Men with Rising PSA after Definitive Local Therapy June 12, 2023 From Vaccitech plc Via GlobeNewswire Over $4M Bet On Diversified Healthcare Trust? Check Out These 4 Stocks Under $5 Insiders Are Aggressively Buying June 02, 2023 Via Benzinga Vaccitech Presents Interim Data from Phase 1b/2 Study of VTP-200 at 35th Annual International Papillomavirus Conference (IPVC) Highlighting Favorable Tolerability and Immunogenicity Profile April 17, 2023 From Vaccitech plc Via GlobeNewswire 7 Thrilling Biotech Stocks for Aggressive Investors to Buy April 05, 2023 Via InvestorPlace Vaccitech Announces Positive Topline Final Data for HBV002 Study in People with Chronic Hepatitis B March 28, 2023 From Vaccitech plc Via GlobeNewswire 12 Health Care Stocks Moving In Friday's Intraday Session March 24, 2023 Via Benzinga Why Scholastic Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Friday's Mid-Day Session March 24, 2023 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.